Wired News – Pfizer Announced an Agreement to Develop and Commercialize Basilea’s Antifungal CRESEMBA in China and the Asia/ Pacific Region
Stock Monitor: Immune Pharma Post Earnings Reporting
LONDON, UK / ACCESSWIRE / December 04, 2017 / Active-Investors issued a free report on Pfizer, Inc. (NYSE: PFE), which is readily accessible upon registration at www.active-investors.com/registration-sg/?symbol=PFE as the Company's latest news hit the wire. On December 01, 2017, the Company declared that it has signed an agreement with Basilea Pharmaceutica Ltd, pursuant to which Pfizer will be granted exclusive rights to develop and commercialize CRESEMBA (isavuconazole) in China and several countries in the Asia/Pacific region. Sign up now for our free research reports at:
www.active-investors.com/registration-sg
Active-Investors.com is currently working on the research report for Immune Pharmaceuticals Inc. (NASDAQ: IMNP), which also belongs to the Healthcare sector as the Company Pfizer. Do not miss out and become a member today for free to access this upcoming report at:
www.active-investors.com/registration-sg/?symbol=IMNP
Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Pfizer most recent news is on our radar and we have decided to include it on our blog post. Today's free coverage is available at:
www.active-investors.com/registration-sg/?symbol=PFE
Terms of the Agreement
Pfizer will have exclusive rights to develop, distribute, and commercialize CRESEMBA in 16 Asia/Pacific countries and China, including Hong Kong and Macao, but excluding Japan. Additionally, Pfizer will also become the marketing authorization holder for the Asia/Pacific Region and China.
Basilea will receive an upfront payment of USD 3 million and is eligible to receive up to USD 223 million additional payments upon achievement of pre-specified regulatory and commercial milestones related to China and the Asia/Pacific region.
Basilea will receive royalties in the mid-teen range on Pfizer's sales in the territory. The agreement is subject to customary conditions and regulatory approvals.
Pfizer's Extensive Geographic Footprint in Asia/Pacific (APAC) and China Will Help Address Unmet Medical Needs in Area of Anti-Infectives
Suneet Varma, Global President of Pfizer APAC, Greater China, and Global Brands, stated that the Company is excited to extend its partnership with Basilea, a company that shares passion and commitment to confronting the global challenges of infectious disease management. Suneet believes that Pfizer's extensive geographic footprint in APAC and China, together with its expertise in successfully commercializing innovative medicines, will enable the Company to continue to address the unmet medical needs of patients, especially in the area of anti-infectives.
Pfizer Obtained Rights to CRESEMBA in Europe in July
On June 14, 2017, Pfizer entered into a license agreement with Basilea to market and manufacture CRESEMBA and to exclusively commercialize the drug in Europe (excluding the Nordics), Russia, Turkey, and Israel. Since that time, Pfizer assumed responsibility for the commercialization of CRESEMBA in Austria, France, Germany, Italy, and the United Kingdom. Pfizer successfully launched CRESEMBA in Spain in November 2017, with additional launches expected in 2018 and beyond.
Avir Pharma to Distribute CRESEMBA in Canada
In June 2017, Basilea Pharmaceutica International Ltd entered into a distribution and license agreement with Avir Pharma Inc., wherein Avir was granted an exclusive license to commercialize isavuconazole and ceftobiprole in the Canadian market. Avir also planned to apply for a marketing authorization for isavuconazole in Canada.
About CRESEMBA (Isavuconazole)
CRESEMBA is an intravenous, novel antifungal medicine for the treatment of adult patients with diagnosed invasive aspergillosis and mucormycosis. It received marketing authorization in Europe for the treatment of adult patients with invasive aspergillosis and for the treatment of adult patients with mucormycosis for whom amphotericin B is inappropriate, and was approved in the United States for patients 18 years of age and older in the treatment of invasive aspergillosis and invasive mucormycosis.
Invasive aspergillosis and mucormycosis are invasive fungal diseases (IFDs) that are an increasingly common complication associated with high morbidity and mortality among immunocompromised patients such as those with advanced HIV infection and those with cancer.
Stock Performance Snapshot
December 01, 2017 - At Friday's closing bell, Pfizer's stock slightly climbed 0.25%, ending the trading session at $36.35.
Volume traded for the day: 18.18 million shares, which was above the 3-month average volume of 16.31 million shares.
Stock performance in the last month – up 3.09%; previous three-month period – up 7.04%; past twelve-month period – up 15.54%; and year-to-date - up 11.92%
After last Friday's close, Pfizer's market cap was at $216.37 billion.
Price to Earnings (P/E) ratio was at 22.33.
The stock has a dividend yield of 3.52%.
The stock is part of the Healthcare sector, categorized under the Drug Manufacturers - Major industry.
Active-Investors:
Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
A-I has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charter-holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: info@active-investors.com
Phone number: 73 29 92 6381
Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: Active-Investors
